From todays Wilson’s report
NSCLC registrational trial progression continues. This new data continues to strengthen the clinical case for advancement of Efti in NSCLC. Immutep continue to finalise registrational trial design (Phase II/III) to evaluate Efti in combination with anti-PD-1 assets (including potential for a triple chemotherapy combination) in a 1L setting. We are anticipating updates on the outcomes of FDA discussions in the current quarter, which will provide more clarity as to trial timelines, but also financial requirements
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $451.2M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.0¢ | $304.6K | 988.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20078 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/02/2025 (20 minute delay) ? |
| IMM (ASX) Chart |